Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).

Tobias MonscheinSarinah DekanyTobias ZrzavyMarkus PonleitnerPatrick AltmannGabriel BstehBarbara KornekPaulus RommerChristian EnzingerFranziska Di PauliJörg KrausThomas BergerFritz LeutmezerMichael Gugernull null

Published in: Journal of neurology (2023)

The effectiveness of natalizumab in patients with active relapsing-remitting multiple sclerosis (RRMS) could be confirmed in our real-world cohort even after follow-up of up to 14 years, though after year 10, there were less than 100 remaining patients. A low number of AE were reported in this nationwide registry study, establishing Natalizumab's favourable safety profile during long-term use.

Keyphrases

multiple sclerosis
white matter
end stage renal disease
newly diagnosed
chronic kidney disease
randomized controlled trial
ejection fraction
systematic review
rheumatoid arthritis
machine learning